Stock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan

Stock Track

02-13

Ascendis Pharma A/S (ASND) shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.

The Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares (ADSs). It also plans to net settle certain Restricted Stock Units (RSUs) for around $9 million, preserving a total of approximately 200,000 ADSs held as treasury shares.

Ascendis reported Q4 2024 revenue of €173.9 million, beating estimates of €111.2 million, driven by strong demand for its growth hormone deficiency treatment SKYTROFA and hypoparathyroidism drug YORVIPATH. The company expressed confidence in continued strong revenue growth, aided by potential label expansions and new product launches in the pipeline, including its TransCon CNP drug for achondroplasia in children.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1142639987"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142639987\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1142639987?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 05:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142639987","market":"us","top_or_hot":-1,"title":"Stock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan","media":"Stock Track","content":"<p>Ascendis Pharma A/S (ASND) shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.</p>\n\n<p>The Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares (ADSs). It also plans to net settle certain Restricted Stock Units (RSUs) for around $9 million, preserving a total of approximately 200,000 ADSs held as treasury shares.</p>\n\n<p>Ascendis reported Q4 2024 revenue of €173.9 million, beating estimates of €111.2 million, driven by strong demand for its growth hormone deficiency treatment SKYTROFA and hypoparathyroidism drug YORVIPATH. The company expressed confidence in continued strong revenue growth, aided by potential label expansions and new product launches in the pipeline, including its TransCon CNP drug for achondroplasia in children.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-13 05:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Ascendis Pharma A/S (ASND) shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.</p>\n\n<p>The Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares (ADSs). It also plans to net settle certain Restricted Stock Units (RSUs) for around $9 million, preserving a total of approximately 200,000 ADSs held as treasury shares.</p>\n\n<p>Ascendis reported Q4 2024 revenue of €173.9 million, beating estimates of €111.2 million, driven by strong demand for its growth hormone deficiency treatment SKYTROFA and hypoparathyroidism drug YORVIPATH. The company expressed confidence in continued strong revenue growth, aided by potential label expansions and new product launches in the pipeline, including its TransCon CNP drug for achondroplasia in children.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASND","symbol_name":"Ascendis Pharma A/S","start_time":0,"source_url":"","article_id":"1142639987","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142639987","pubTimestamp":1739396320,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ascendis Pharma A/S  shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.The Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares . It also plans to net settle certain Restricted Stock Units  for around $9 million, preserving a total of approximately 200,000 ADSs held as treasur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ASND":"Ascendis Pharma A/S"},"translate_title":"股票追踪Ascendis Pharma因第四季度业绩和回购计划盘后飙升6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":1},"content_text":"Ascendis Pharma A/S (ASND) shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.\nThe Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares (ADSs). It also plans to net settle certain Restricted Stock Units (RSUs) for around $9 million, preserving a total of approximately 200,000 ADSs held as treasury shares.\nAscendis reported Q4 2024 revenue of €173.9 million, beating estimates of €111.2 million, driven by strong demand for its growth hormone deficiency treatment SKYTROFA and hypoparathyroidism drug YORVIPATH. The company expressed confidence in continued strong revenue growth, aided by potential label expansions and new product launches in the pipeline, including its TransCon CNP drug for achondroplasia in children.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"buyback,movement","news_rank":0,"symbols":[],"gpt_button":1}}}